Premium
PAVmed Inc (PAVM)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, Jan. 13, 2025 Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW...
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid...
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.004 | -0.616332819723 | 0.649 | 0.6973 | 0.621 | 104814 | 0.65846789 | CS |
| 4 | 0.005 | 0.78125 | 0.64 | 0.6973 | 0.5719 | 136243 | 0.63542213 | CS |
| 12 | -0.495 | -43.4210526316 | 1.14 | 1.25 | 0.5719 | 182868 | 0.73038771 | CS |
| 26 | -0.1108 | -14.6599629532 | 0.7558 | 1.9 | 0.5719 | 113359 | 0.86384295 | CS |
| 52 | -1.375 | -68.0693069307 | 2.02 | 3.5 | 0.5719 | 89435 | 1.18167297 | CS |
| 156 | -23.355 | -97.3125 | 24 | 35.1 | 0.5719 | 568898 | 13.81497401 | CS |
| 260 | -21.855 | -97.1333333333 | 22.5 | 145.5 | 0.5719 | 1146074 | 47.91799365 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
